Antiviral Agents - 1st Edition - ISBN: 9780124058804, 9780124055377

Antiviral Agents, Volume 67

1st Edition

Editors: Erik De Clercq
eBook ISBN: 9780124055377
Hardcover ISBN: 9780124058804
Imprint: Academic Press
Published Date: 12th August 2013
Page Count: 384
Tax/VAT will be calculated at check-out Price includes VAT (GST)
25% off
25% off
25% off
25% off
25% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
30% off
30% off
30% off
30% off
30% off
20% off
20% off
256.00
192.00
192.00
192.00
192.00
192.00
204.80
204.80
155.00
108.50
108.50
108.50
108.50
108.50
124.00
124.00
195.00
136.50
136.50
136.50
136.50
136.50
156.00
156.00
Unavailable
Price includes VAT (GST)
DRM-Free

Easy - Download and start reading immediately. There’s no activation process to access eBooks; all eBooks are fully searchable, and enabled for copying, pasting, and printing.

Flexible - Read on multiple operating systems and devices. Easily read eBooks on smart phones, computers, or any eBook readers, including Kindle.

Open - Buy once, receive and download all available eBook formats, including PDF, EPUB, and Mobi (for Kindle).

Institutional Access

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

Preface

References

Contributors

Chapter One. Antiviral Agents for Herpes Simplex Virus

Abbreviations

1 Introduction

2 Historical Overview: Therapies for HSV Infections

3 Clinical Experience with ACV, VACV, and FCV Through Two Decades

4 Antiviral Drug Resistance

5 Novel Approaches to HSV Chemotherapy

6 Prospects for Novel Antiviral Compounds and Vaccines

7 Conclusion

Conflict of Interest

References

Further Reading

Chapter Two. Nucleotide Prodrugs for the Treatment of HCV Infection

Abbreviations

1 Introduction

2 Nucleoside Inhibitors

3 Nucleotide Prodrugs

4 Conclusion

Conflict of Interest

References

Chapter Three. HIV Integrase Inhibitors: 20-Year Landmark and Challenges

Abbreviations

1 Introduction

2 Requirement of IN for HIV Replication

3 IN Structure

4 The INSTIs

5 Challenges

6 Conclusion

Conflict of Interest

References

Chapter Four. Advances in the Treatment of Varicella-Zoster Virus Infections

Abbreviations

1 Introduction

2 Vaccination Strategies and Postexposure Prophylaxis

3 Existing Antiviral Treatments

4 Medical Need for New Anti-VZV Agents

5 Development of Novel Anti-VZV Agents

6 Candidate Anti-VZV Drugs

7 Perspectives

8 Conclusion

Conflict of Interest

Acknowledgments

References

Chapter Five. Hepatitis C Virus: Standard-of-Care Treatment

Abbreviations

1 Introduction

2 Curing HCV Infection

3 Interferons

4 Ribavirin

5 Direct HCV Inhibitors (DAAs and HTAs)

6 Interferon-Based Strategies in 2013

7 Interferon-Free Regimens in 2014 and Onward

8 Conclusion

Conflict of Interest

References

Chapter Six. Influenza Virus Resistance to Antiviral Therapy

Abbreviations

1 Introduction

2 Antiviral Drugs Under Development

3 Resistance to Antiviral Therapy

4 Mechanisms of Resistance to NAIs

5 Permissive and Compensatory Mechanisms Governing Primary Resistance

6 Effectiveness of NAIs

7 Conclusion

Conflict of Interest

References

Further Reading

Chapter Seven. The Natural Course of Chronic Hepatitis B Virus Infection and Its Management

Abbreviations

1 Introduction

2 A Flashback from the Discovery of HBV to the Recognition of the Wide Spectrum of Chronic HBV Infection

3 Development of Chronic HBV Infection and the Phases in Its Natural Course

4 Complicating and Associated Conditions and Comorbidities

5 Treatment of CHB

6 Future Treatments for CHB

7 Conclusion

Conflict of Interest

References

Chapter Eight. The Holý Trinity: The Acyclic Nucleoside Phosphonates

Abbreviations

1 Introduction

2 HPMPA

3 Cidofovir

4 Adefovir

5 Tenofovir

6 Tenofovir Combinations

7 Tenofovir for the Prevention of HIV Infections

8 Tenofovir for the Treatment of HBV Infections

9 Tenofovir for PMTCT

10 Tenofovir Toxicity

11 GS-7340, GS-9131, GS-9191, GS-9219

12 Conclusion

Conflict of Interest

Acknowledgments

References

Chapter Nine. The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS)

Abbreviations

1 Introduction

2 Reverse Transcriptase

3 Nucleoside Reverse Transcriptase Inhibitors

4 Nonnucleoside Reverse Transcriptase Inhibitors

5 Protease Inhibitors

6 Drug Combinations

7 Clinical Aspects

8 Preexposure Prophylaxis

9 Prevention of Mother-to-Child Transmission

10 Children

11 Toxicity

12 Adherence (Compliance)

13 Resistance

14 New NRTIs, NNRTIs, and PIs

15 Conclusion

Conflict of Interest

Acknowledgments

References

Index


Description

This new volume of Advances in Pharmacology explores the current state of antiviral agents. Chapters cover such topics as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV. With a variety of chapters and the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike.

Key Features

  • Explores the current state of anti-viral agents
  • Chapters cover a variety of topics such as virus entry inhibitors, interferon-free drug combinations, and antiviral agents for HSV
  • With the best authors in the field, the volume is an essential resource for pharmacologists, immunologists and biochemists alike

Readership

Pharmacologists, immunologists, and biochemists


Details

No. of pages:
384
Language:
English
Copyright:
© Academic Press 2013
Published:
Imprint:
Academic Press
eBook ISBN:
9780124055377
Hardcover ISBN:
9780124058804

About the Editors

Erik De Clercq Editor